A Clinical Development Plan (CDP) is a comprehensive, strategic development plan that describes how a drug substance, biologic, or medical device is clinically investigated from early development through to marketing authorization. It consolidates target indications, study sequence, evidence strategy, safety and efficacy data, and regulatory interactions into a consistent roadmap. In practice, the CDP is frequently used as a guiding framework to align clinical, nonclinical, and CMC (Chemistry, Manufacturing and Controls) activities and to justify investment and resource decisions.
For sponsors, CROs, and internal functions such as Clinical Operations, Biostatistics, Medical Affairs, and Regulatory Affairs, the CDP is a central steering document. It does not replace detailed protocols or the Clinical Study Report, but it establishes a common rationale for why a particular study is conducted when, which endpoints are required, and how the benefit-risk evidence should be built. In EU and German contexts, it is particularly useful for systematically addressing requirements from EU Regulation 536/2014 (CTR) and ICH guidelines (e.g., ICH E6(R3) and ICH E8(R1)).
Purpose and Value in Clinical Development
The CDP describes the clinical evidence chain: from first-in-human studies through dose finding and proof-of-concept to pivotal registration studies. It makes assumptions explicit (e.g., expected effect size, target population, comparator therapy) and defines decision points (“Go/No-Go”). This helps design study programs that are regulatorily plausible, medically sound, and economically viable.
Another benefit lies in consistency: if study phases, endpoints, inclusion and exclusion criteria, or safety monitoring vary significantly between studies, the overall picture becomes difficult to explain during the marketing authorization process. The CDP counteracts this and facilitates later dossiers such as the electronic Common Technical Document (eCTD), because the rationales are already prepared.
From a project perspective, a CDP is also a communication tool: it helps align stakeholders on a common prioritization, for example when multiple indications are conceivable or when early data are only of limited robustness. For financing and portfolio decisions, it is important that the clinical strategy clearly demonstrates which evidence is needed in which sequence to reach value inflection points.
Typical Content and Structure of a CDP
In terms of content, a CDP typically includes: target product profile, medical need and competitive landscape, clinical rationale, development objectives per phase, planned studies (design, population, endpoints, statistical assumptions), safety strategy (pharmacovigilance, Risk Management Plan), CMC and supply chain aspects (e.g., comparability, stability), and a plan for regulatory interactions (Scientific Advice, meetings with authorities).
Many companies supplement this with a timeline and milestone plan, budget assumptions, risks and dependencies (e.g., recruitment feasibility, availability of investigational sites, changes in standard of care). For medical devices, clinical evaluation (Clinical Evaluation Report) and post-market clinical follow-up may be included as additional components, particularly under MDR 2017/745.
In practice, a tabular overview of study blocks has proven effective: phase, population, randomization/blinding, primary and secondary endpoints, duration, sample size range, and planned analyses. This overview then serves as the basis for subsequent detailed documents such as the protocol, monitoring plan, data management plan, and vendor scopes.
Regulatory Context (EU/Germany) and Interaction with Authorities
In Europe, a CDP serves as the foundation for obtaining early regulatory feedback. A structured CDP facilitates Scientific Advice with EMA or national authorities and supports the preparation of CTIS submissions under CTR 536/2014. It can also maintain consistent argumentation for endpoints, subgroups, and planned amendments when the program spans multiple years.
It is important that a CDP remains dynamic: changes in safety data, new competitor data, or new guidelines (e.g., updates to ICH E6(R3)) must be incorporated into the development strategy in a traceable manner. This reduces the risk that authorities will request additional studies in later phases or assess the evidence as inconsistent.
Role in Project Management: Sponsor, CRO, and Governance
In daily operations, the CDP is a steering instrument for governance bodies, such as the Steering Committee or Development Committee. It defines responsibilities, dependencies, and decision logic. For CROs, it is valuable for planning feasibility studies, recruitment strategy, monitoring approach (risk-based monitoring, central monitoring), and data management early on.
Typical interfaces exist with the Trial Master File, Standard Operating Procedures, and Quality Management System. A CDP can, for example, specify when a database lock is planned, which interim analyses are foreseen, and how data integrity will be ensured. This allows operational plans to be linked with the strategic evidence logic.
A common practical scenario involves protocol amendments: when the program comprises multiple studies, the CDP should clearly define how findings from one study feed into the next and when an amendment is appropriate. This facilitates consistent communication with ethics committees and authorities and reduces operational friction.
FAQ and Regulatory References
When should a Clinical Development Plan be created?
At the latest before the transition into clinical development, often already in the late preclinical phase, so that first-in-human studies and the long-term evidence strategy are aligned.
Is a CDP a regulatory requirement?
A CDP is generally not mandatory as a formal submission, but it is indirectly expected because it makes the coherence of the development program transparent and provides structured support for Scientific Advice.
How often should a CDP be updated?
Whenever new data or external factors influence the development logic, such as relevant safety findings, changes in standard of care, or important feedback from authorities.
- EU Regulation (EU) No 536/2014 on clinical trials (CTR)
- Regulation (EU) 2017/745 on medical devices (MDR)
- ICH E6(R3) Good Clinical Practice
- ICH E8(R1) General Considerations for Clinical Studies